GILD has a higher market value than 97.42% of US stocks; more precisely, its current market capitalization is $75,486,744,318.
GILD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 307.83 -- higher than 88.8% of US-listed equities with positive expected earnings growth.
The volatility of Gilead Sciences Inc's share price is greater than that of only 3.91% US stocks with at least 200 days of trading history.
Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are ATVI, ADI, BIIB, AMAT, and RACE.
GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Gilead Sciences Inc. To summarize, we found that Gilead Sciences Inc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. As for the metrics that stood out in our discounted cash flow analysis of Gilead Sciences Inc, consider:
The company's compound free cash flow growth rate over the past 5.45 years comes in at -0.06%; that's greater than merely 17.6% of US stocks we're applying DCF forecasting to.
The company has produced more trailing twelve month cash flow than 93.51% of its sector Healthcare.
Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Gilead Sciences Inc? See CPIX, LMAT, HAPP, ILMN, and ZTS.
New month... new stock considerations. I can't believe that October is already here... the final quarter of 2020. Seeing how fast time blows by simply reminds me to stay invested no matter how crazy the market seems to be. We have witnessed some pretty harsh declines this year only to...
The Latest: President Donald Trump is being treated with antiviral drug, Gilead's (GILD) remdesivir, at a U.S. military hospital, while campaign manager Bill Stepien and ex-White House adviser Kellyanne Conway have also tested positive.The president is also taking Regeneron's antibody cocktail as reported last night.Senators Thom Tillis from North Carolina and Mike...
The European drugs regulator said on Friday its safety committee was reviewing reports of acute kidney injury in some COVID-19 patients who had been given Gilead Sciences Inc's remdesivir. Kidney injury can be caused by COVID-19 as well as other factors such as diabetes, the EMA said in a statement.
Reports and Data has added a new report titled Global T-Cell Therapy Market to its ever-expanding repository, which aims to offers valuable insights into the T-Cell Therapy industry with regards to the market share, market size, market valuation, and regional